Venus Medtech (Hangzhou) Inc

02500

Company Profile

  • Business description

    Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically majority of the revenue is derived from Mainland China.

  • Contact

    No. 88, Jiangling Road
    Room 311, 3rd Floor, Block 2
    Binjiang District
    Hangzhou310051
    CHN

    T: +86 57187772180

    https://www.venusmedtech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2025

    Employees

    691

Stocks News & Analysis

stocks

After Earnings, is Alphabet stock a buy, a sell, or fairly valued?

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks

Moated ASX share crashes amid weak trading update

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,025.4058.700.65%
CAC 407,857.3656.480.72%
DAX 4024,217.37247.011.03%
Dow JONES (US)44,632.99204.57-0.46%
FTSE 1009,136.3254.880.60%
HKSE25,415.94108.51-0.43%
NASDAQ21,098.2980.29-0.38%
Nikkei 22540,721.0146.460.11%
NZX 50 Index12,937.020.610.00%
S&P 5006,370.8618.91-0.30%
S&P/ASX 2008,766.5061.900.71%
SSE Composite Index3,628.5318.820.52%

Market Movers